Pain Medication Beliefs Can Enhance (or Impair) Pain Relief

PainRelief.com Interview with:
Leon Timmerman, PhD
St Antonius Hospital, Department of Anesthesiology
Intensive Care and Pain Medicine
The Netherlands

Leon Timmerman, PhD St Antonius Hospital, Department of Anesthesiology Intensive Care and Pain Medicine The Netherlands
Dr. Timmerman

PainRelief.com:  What is the background for this study?  What are the main findings?

Response: Chronic pain is commonly treated with pain medication. However, the results of pharmacological treatment are often poor. One of the reasons might be that half of the patients do not use their medication as prescribed. Underuse as well as overuse are common and have been described to result in reduced treatment effect, health care risks and unnecessary treatment changes. The are many risks factors described for non-adherent behavior.

The way people think about their pain medication have been shown to be related to the way they use their medication. With this study, we confirmed this relation with a prospective study. Baseline beliefs about pain medication, measured by ‘Pain Medication Attitudes Questionnaire’,  were found to be related to underuse of pain medication, the occurrence of side effects and patient satisfaction after three months.  

Continue reading

Off-Label Gabapentinoid Prescriptions for Cancer Pain Relief Double

PainRelief.com Interview with:
Alex Fauer, RN, OCN®
Ph.D. Candidate
University of Michigan School of Nursing

PainRelief.com Interview with: Alex Fauer, RN, OCN® Ph.D. Candidate University of Michigan School of Nursing

PainRelief.com:  What are the main findings?

Response: Our primary finding of the paper is that the age-, sex-, and US region-adjusted percentage of adults who used a gabapentinoid increased from 2.34% to 5.60% from 2005 to 2015. The total number of gabapentinoid prescriptions  filled  among  US  adults diagnosed with  cancer was  approximately  1.19  million in 2005, but increased to 3.52 million in 2015.

We also found that adults aged 18-44 were the highest users of gabapentinoids.

Continue reading